Related content

Retinal pigment epithelial tear after intravitreal ranibizumab for subfoveal CNV secondary to AMD

By Apte Rajendra  

International Ophthalmology, Vol. 27, Iss. 1, 2007-02 ,pp. : 59-61

Springer Publishing Company

Access to resources Recommend Favorite

Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia

By Rishi Pukhraj  

Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 246, Iss. 4, 2008-04 ,pp. : 619-621

Springer Publishing Company

Access to resources Recommend Favorite

Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010

By Cohen Salomon   Dubois Lise   Ayrault Sandrine   Dourmad Pauline   Delahaye-Mazza Corinne   Fajnkuchen Franck   Nghiem-Buffet Sylvia   Quentel Gabriel   Tadayoni Ramin  

Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 251, Iss. 11, 2013-11 ,pp. : 2499-2503

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research

By Wolf Armin   Kampik Anselm  

Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 252, Iss. 4, 2014-04 ,pp. : 647-655

Springer Publishing Company

Access to resources Recommend Favorite

Intravitreale Anti-VEGF-Therapie mit Bevacizumab bei neovaskulärer AMD

By Schaal K.B.   Engler C.   Schütt F.   Scheuerle A.   Dithmar S.  

Der Ophthalmologe, Vol. 105, Iss. 6, 2008-06 ,pp. : 538-543

Springer Publishing Company

Access to resources Recommend Favorite